IRD Butterfly Strategy
IRD (Opus Genetics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
IRD (Opus Genetics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $359.2M, a beta of 0.63 versus the broader market, a 52-week range of 0.9-5.81, average daily share volume of 910K, a public-listing history dating back to 2015, approximately 18 full-time employees. These structural characteristics shape how IRD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.63 indicates IRD has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a butterfly on IRD?
A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration.
Current IRD snapshot
As of May 15, 2026, spot at $4.79, ATM IV 154.30%, IV rank 32.19%, expected move 44.24%. The butterfly on IRD below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this butterfly structure on IRD specifically: IRD IV at 154.30% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 44.24% (roughly $2.12 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IRD expiries trade a higher absolute premium for lower per-day decay. Position sizing on IRD should anchor to the underlying notional of $4.79 per share and to the trader's directional view on IRD stock.
IRD butterfly setup
The IRD butterfly below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IRD near $4.79, the first option leg uses a $4.55 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IRD chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IRD shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.55 | N/A |
| Sell 2 | Call | $4.79 | N/A |
| Buy 1 | Call | $5.03 | N/A |
IRD butterfly risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit.
IRD butterfly payoff curve
Modeled P&L at expiration across a range of underlying prices for the butterfly on IRD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use butterfly on IRD
Butterflies on IRD are pinning bets - traders use them when they expect IRD to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
IRD thesis for this butterfly
The market-implied 1-standard-deviation range for IRD extends from approximately $2.67 on the downside to $6.91 on the upside. A IRD long call butterfly is a pinning play: it pays maximum at the middle strike if IRD settles there at expiration, with the wing legs capping both the cost and the maximum loss to the net debit. Current IRD IV rank near 32.19% is mid-range against its 1-year distribution, so the IV signal is neutral; the butterfly thesis on IRD should anchor more to the directional view and the expected-move geometry. As a Healthcare name, IRD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IRD-specific events.
IRD butterfly positions are structurally neutral / pin (limited-risk, limited-reward); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IRD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IRD alongside the broader basket even when IRD-specific fundamentals are unchanged. Always rebuild the position from current IRD chain quotes before placing a trade.
Frequently asked questions
- What is a butterfly on IRD?
- A butterfly on IRD is the butterfly strategy applied to IRD (stock). The strategy is structurally neutral / pin (limited-risk, limited-reward): A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration. With IRD stock trading near $4.79, the strikes shown on this page are snapped to the nearest listed IRD chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are IRD butterfly max profit and max loss calculated?
- Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit. For the IRD butterfly priced from the end-of-day chain at a 30-day expiry (ATM IV 154.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IRD butterfly?
- The breakeven for the IRD butterfly priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IRD market-implied 1-standard-deviation expected move is approximately 44.24%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a butterfly on IRD?
- Butterflies on IRD are pinning bets - traders use them when they expect IRD to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
- How does current IRD implied volatility affect this butterfly?
- IRD ATM IV is at 154.30% with IV rank near 32.19%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.